Business Services Industry
Odetics Inc. Reports Second Quarter Fiscal 2003 Results
Business Wire, Oct 23, 2002
Business Editors
ANAHEIM, Calif.--(BUSINESS WIRE)--Oct. 23, 2002
For its second quarter ended Sept. 30, 2002, Odetics Inc. (Nasdaq:ODETA) (Nasdaq:ODETB) today reported a loss from continuing operations of $2.6 million or $0.18 per share, compared with a loss of $4.3 million or $0.41 per share, reported for the second quarter of the previous fiscal year.
For the second quarter ended Sept. 30, 2002, Odetics net sales and contract revenues were $13.7 million, compared with $16 million reported in the second quarter of the previous fiscal year. Revenues in the second quarter of the previous fiscal year included $3.4 million of sales from the company's former Gyyr CCTV Product line, which was sold during the quarter ended Sept. 30, 2001.
Greg Miner, chief executive officer, stated: "In spite of tough business conditions, overall revenues on our base business increased approximately 9% compared to the second quarter of 2001, and each of the Odetics reporting segments posted continued year over year growth in the current quarter. Gross profit in the current quarter was approximately 39% of net sales, up slightly compared to last year's second quarter and operating expenses, excluding the restructuring charges taken in last year's second quarter, were reduced approximately 20%. Overall operating losses were narrower by nearly 60% in the current year's second quarter compared to last year."
Miner added: "During the second quarter ended September 30, 2002, we shipped new products in both our MAXxess and Zyfer businesses. This revenue includes IMS chemical detectors that our MAXxess subsidiary, in conjunction with our partner Draeger Safety, delivered to DARPA for testing and evaluation by the DoD Immune Building Program.
"Secondly, our Zyfer subsidiary received a significant order from Harris Corporation for production quantities of its newest SAASM GPS-aided product called GSync(TM). We believe that SAASM will be an important building block in secure synchronization of critical network communications. Zyfer's revenues in the quarter ended September 30, 2002 increased 106% compared to the same period of last year and Zyfer now represents approximately 18% of our total revenues."
About Odetics
Odetics products address the security and data management needs of the transportation, defense, facility security, and broadcast industries. Odetics is a market leader for video-based sensors used for surface transportation, a developer of integrated systems for facility security and trace detection of dangerous chemicals and explosives, and is a provider of automation systems to the broadcast industry. Odetics is also a leading provider of equipment built around specific government mandates for secured communications.
Odetics has headquarters in Anaheim. Investors are encouraged to contact the company at 714/774-5000, or at www.odetics.com.
Important Notice
This news release contains statements that may be deemed to be forward-looking. These forward-looking statements may include statements about market acceptance of the company's products and other statements relating to the operating results of Odetics or its subsidiaries. These forward-looking statements speak only as of the date hereof and are based upon the information available to the company at this time. Such information is subject to change, and the company will not necessarily inform you of such changes. Actual results could differ materially from those projected in the forward-looking statements as a result of risk factors such as: incorrect assumptions regarding market demand, the significant uncertainty of market acceptance of new products by both distributors and end-user customers, general economic and political issues, including the continuing significant economic slowdown and volatility in the technology sector issues related to the supply, manufacturing and quality assurance of the company's products; competition (including new and directly competitive products from others), the volume of its sales and pricing pressures, the loss of a key customer, the delay or cancellation of a large customer order in any period; changes in its product or customer mix, and such other factors identified in Odetics' Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
Investors are strongly encouraged to review the risk factors set forth in Odetics' most recent SEC filings.
Odetics Inc.
Summary Financial Data
(in thousands, except per share amounts)
Three Months Ended Six Months Ended
Sept. 30, Sept. 30,
Consolidated Statement
of Operations 2001 2002 2001 2002
Net sales and contract
revenues:
Net sales $10,302 $8,026 $21,002 $17,114
Contract revenues 5,675 5,721 11,359 11,936
Total net sales and
contract revenues 15,977 13,747 32,361 29,050
Costs and expenses:
Cost of sales 6,253 4,773 13,430 9,356
Cost of contract revenues 3,575 3,585 7,395 7,684
Gross profit 6,149 5,389 11,536 12,010
Selling, general and
administrative expense 6,408 5,408 13,418 10,597
Research and development
expense 2,318 1,586 4,455 3,340
Restructuring charge 1,422 0 1,422 0
Total operating expenses 10,148 6,994 19,295 13,937
Operating loss (3,999) (1,605) (7,759) (1,927)
Non-operating items
Other income 1,072 (25) 1,072 580
Interest expense, net (1,190) (41) (1,785) (596)
Loss before income taxes (4,117) (1,671) (8,472) (1,943)
Income tax benefit 0 0 0 0
Loss from continuing
operations before minority
interest (4,117) (1,671) (8,472) (1,943)
Minority interest in
earnings of subsidiary 174 946 174 1,974
Loss from continuing
operations (4,291) (2,617) (8,646) (3,917)
Income (loss) from
discontinued operations
(including loss on disposal
of $8,361),
net of taxes of $0 (10,873) 0 (13,843) 0
Extraordinary loss from
early extinguishment of
debt, net of tax of $0 0 0 (450) 0
($15,164) ($2,617) ($22,939) ($3,917)
Net loss
Income (loss) per share:
Basic and diluted
(Loss) from
continuing
operations ($0.41) ($0.18) ($0.82) ($0.29)
Income (loss) from
discontinued
operations (1.03) 0.00 (1.31) 0.00
Extraordinary
(loss) from the
early
extinguishment of
debt 0.00 0.00 (0.04) 0.00
(Loss) per share ($1.43) ($0.18) ($2.17) ($0.29)
Shares used in calculating
loss per share:
Basic and diluted 10,579 14,283 10,566 13,435
Odetics Inc.
Summary Financial Data
(in thousands, except per share amounts)
Three Months Ended Six Months Ended
Sept. 30, Sept. 30,
2001 2002 2001 2002
Revenues by segment:
Iteris $9,637 $9,684 $17,349 $19,943
Video Products 5,160 1,628 12,588 4,301
Telecom Products 1,180 2,435 2,424 4,806
$15,977 $13,747 $32,361 $29,050
(audited) (unaudited)
Balance Sheet Highlights 03/31/02 09/30/02
Current assets $24,721 $25,148
Property, plant &
equipment, net $17,720 $3,580
Other assets $9,797 $12,959
Current liabilities $34,048 $16,295
Shareholders' equity $5,255 $4,143
- 5 Rules for Immediate Annuities
- Death in the Family: 12 Things to Do Now
- Dumbest Things You Do With Your Money
- 6 Online Networking Mistakes to Avoid
- 401(k) Mistakes to Avoid
- 5 Economic Scenarios to Keep You Up at Night
- The Real ‘Best Places to Retire’
- Best Credit Cards for You
- 12 Tough Questions to Ask Your Parents
- The Real ‘Best Colleges’
- Home Buyer Tax Credit: How to Cash In
- Why You Shouldn't Bash Cash
- 8 Phony 'Bargains' and Better Alternatives
- Danger: 3 Debit Card Scams to Avoid
- 6 Myths About Gas Mileage
- 29 Fees We Hate Most
- Quick and Easy Ways to Boost Returns
- Best Stocks to Buy Now
- Lower Your Taxes: 10 Moves to Make Now
- New Jobs: 8 Lessons from Real-Life Career Switchers
- The New Job Market: Who Wins and Who Loses?
- Health Care Reform's Public Option: Everything You Need to Know
- Volunteer Work When Unemployed: Should You Work for Free?
- Whose Recovery Is This?
- Long-Term-Care Insurance: 4 Biggest Risks to Avoid
Most Recent Business Articles
- Psyadon Pharmaceuticals, Inc. Announces Regulatory Milestones and the Initiation of a Clinical Trial of Ecopipam in Lesch-Nyhan Disease
- Emergence of “Femtomedicine” - New Frontier of Biomed Sciences - Reported at First Global Congress on Nano Medicine
- Research and Markets: Ethiopia Power Market Outlook to 2020
- Research and Markets: Orphan Drugs in Asia-Pacific: from Designation to Pricing, Funding & Market Access
- Research and Markets: Now You See It - TV Program Sponsorship & Product Placement in China
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FHM Features Anna Benson, Baseball's Hottest Wife
- Building a DNA database: the federal government has just enacted two bills related to DNA. The first would drive the collection of DNA from all infants. The second would attempt to prevent the DNA that is collected from being misused
- America's most wanted j-o-b-s - 10 hottest employment opportunities
- Developmental sequence in small groups


